The 161533 TriKE, which incorporates a modified human IL-15 as a crosslinker between the specific scFvs against CD16 and CD33, a myeloid-specific member of the sialic acid-binding receptor family which is highly expressed on myeloid leukemia cells, has demonstrated superior anti-tumor activity both in vitro and in preclinical models compared to the 1633 CD16-CD33 BiKE without IL-15 [108]. The gene discussed is CD33; the disease is neoplasm.